Search Results
Results found for "Shane Wright"
- Exciting GPCR Events for Next Year! + GPCR Weekly Rocket Launch ⦿ Oct 28 - Nov 3, 2024
That's right, you're about to level up your knowledge game! keep you on your toes Direct line to all the cool cats in the GPCR community - Networking is key, right
- How Fast Does a Drug Work?
affinity metrics alone, often overlooking how kinetic profiles (onset and offset rates) fundamentally shape and how long it stays bound (k₂) can alter therapeutic profiles dramatically, even if two candidates share Kenakin’s lecture guides you through key questions that should shape your decision-making process: Are Don’t Let Outdated Models Slow Your Next Program The analytical tools that shaped traditional affinity
- Applications of Fluorescent Probes in Confocal Imaging of GPCRs: From Live to Fixed Cells
Right panel, the fluorescent signal is displaced when, after incubating with CELT-327, cells are incubated
- Why “Displacement” Misleads You: Allosteric Binding Demystified
translational strategy, this is where 40 years of pharmacological insight meets the questions you’re asking right
- Involvement of various chemokine/chemokine receptor axes in trafficking and oriented locomotion ...
Chemokines are low molecular weight proteins that their functional activities are achieved by binding
- Fluorescence Polarization in GPCR Research
New generations of fluorophores with improved photostability and brightness will enhance assay sensitivity
- How System-Level GPCR Thinking Prevents Discovery Failures
But HCS only works when assays are built with rigor and powered by the right fluorescent ligands.
- Terry’s Corner, Celtarys' Leap, and the $7B GPCR Horizon
weekly lesson help you apply key concepts like binding, signaling, and kinetics in practical, decision-shaping Maria Majellaro shares her journey to founding Celtarys in "From Lab to Leadership".
- GPCR Drug Discovery at Discovery on Target: Why This Track Is About More Than Receptors
in Boston, the GPCR Drug Discovery track will deliver breakthroughs, bold ideas, and the strategies shaping GPCR , our mission is simple: connect the GPCR community, share knowledge, and accelerate innovation We’re helping shape the conversation. 🚀 Why GPCRs Are Still the Hottest Target Class in Drug Discovery
- Quantifying Receptor Selectivity in Modern Drug Discovery
Kenakin uses a lever analogy where: Efficacy is the weight applied.
- 📰 GPCR Weekly News, March 4 to 10, 2024
Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals Are GLP-1s finding the right
- Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
Chemistry Frontiers 2025 , a conference organized by both the EFMC and the ACSMEDI, in an effort to share She has a lot of experience working for bigger businesses which she now shares as an advisor for startups Sharing the round table discussion with these excellent scientists felt like a dream come true, and Maria This Chemistry Tools session was more industry focused than those before, and Maria shared the floor This was a very enriching experience for Maria, not only did she have a chance to share Celtarys’ technology
- Fentanyl and Xylazine: Why Breathing Fails in Overdose
Without a reversal agent for xylazine, the best defense right now is mechanistic understanding .
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Rodriguez, P.J., et al., Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
- 📰 GPCR Weekly News, June 3 to June 9, 2024
More details will be shared soon, and registration will open in July 2024. Dr. GPCR Event Highlight We are thrilled to share the news of our in-person event in partnership with the binding genes unveiled via RNA polymerase II degradation Growth factor-dependent phosphorylation of Gαi shapes
- 📰 GPCR Weekly News, September 18 to 24, 2023
Bioscience Announces Site Relocation AI can help to speed up drug discovery — but only if we give it the right
- Advantages of Fluorescent Probes in GPCR Assays
Our scientific team can guide you choose or design the right fluorescent ligand for your research.
- 📰 GPCR Weekly News, January 1 to 7, 2024
Officer Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
News from November 25th to December 1st, 2024 Industry News Amgen says obesity drug caused up to 20% weight
- Embark on a GPCR Adventure: Your Weekly Research Expedition! | Oct 21-27, 2024
Let’s keep fostering a collaborative environment for sharing ideas and expanding knowledge! The presentations and discussions sparked new ideas and collaborations, shaping the future of the field
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
Earlier decades relied on Scatchard, Hanes, and other linear transforms to “clean” nonlinear data. Stoichiometry: The Quiet Driver of Curve Shape Two-stage systems expose how easily stoichiometry distorts When a tracer binds two sites with different affinities, curve shape reflects the ratio of affinities may see: Early stopping → potency distortions Different stopping times → incomparable datasets Curve shape Those who invest now shape the breakthroughs that follow.
- Early Stage Biotech Hiring: What Really Holds a Team Together When the Science Starts to Drift
The right ones also know when progress matters more than perfection. 👉 These signals are subtle, but
- From Pipettes to Platforms: The Evolution of GPCR Research
They shaped how questions were asked. Leadership, Luck, and the Lab The episode isn’t just about technology — it’s also about how careers are shaped And those who understand both the legacy and the future of GPCR work are the ones shaping the next era
- GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026
focuses on how GPCR binding affinity experiments are interpreted—and how those interpretations quietly shape This growth reflects something deeper than metrics: a shared demand for clearer interpretation, stronger
- Addex Raises $10 Million In Equity Financing
a healthcare-focused institutional investor, pursuant to which the Company agreed to sell 3,752,202 shares in the form of 625,367 American Depositary Shares (“ADSs”) at a gross purchase price of $6.50 per ADS , which is equivalent to CHF 1.00 per share. Each ADS represents six shares. the “Unregistered Warrants”), as well as unregistered pre-funded warrants to purchase up to 5,478,570 shares
- The Hidden Cost of Unclear Biotech Positioning
Each external interaction becomes reactive, shaped more by incoming questions than by strategic intent This puts the burden of synthesis on the listener , who may not share the same context or priorities. The positioning creates a shared frame before details enter the discussion .
- The Hidden Operating Cadence That’s Actually Driving Your Biotech
And that cadence is shaping everything: timelines, decisions, investor calls, BD traction, internal focus next year is better” → to “our cadence ensures it will be.” ✅ If you want a stronger 2025, start by shaping the one thing that shapes everything else: your operating cadence.
- Addex raises $4.2 million in equity financing
in the form of 550,000 American Depositary Shares (“ADSs”) at a gross purchase price of $1.70 per ADS , which is equivalent to CHF 0.27 per share. Each ADS represents six shares. agreed to issue to Armistice Capital unregistered pre-funded warrants to purchase up to 11,700,000 shares $1.69 with $0.01 payable on exercise as well as unregistered warrants to purchase up to 15,000,000 shares
- Unlock the Hidden Complexity Behind GPCRs—From Terry Kenakin’s Vault
of GPCR-targeted drugs fail—not because of poor chemistry, but because we’ve misunderstood how these shape-shifting
- Understanding Orthosteric Binding: The Key to Drug Action
The receptor may change shape upon binding, affecting how the drug interacts and how effective it will The dynamic interplay of chemical forces shapes drug effectiveness.






















